Tango Therapeutics, Inc. (TNGX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Tango Therapeutics, Inc. reported revenue of $62.38M, up 48.3% from the prior year. The company ran a net loss, with a net margin of -162.9%. It held $398.69M in total assets against $52.51M in total liabilities.
Key ratios (FY2025)
-178.4%
Operating margin
-162.9%
Net margin
-29.3%
Return on equity
+48.3%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $62.38M | $42.07M | $36.53M | $24.86M | $37.04M | $7.66M | — |
| Operating Income | -$111.29M | -$145.59M | -$114.17M | -$111.07M | -$58.19M | -$52.20M | — |
| Net Income | -$101.59M | -$130.30M | -$101.74M | -$108.18M | -$58.23M | -$51.97M | — |
| EPS (Diluted) | $-0.87 | $-1.19 | $-1.08 | $-1.23 | $-0.94 | — | — |
| Total Assets | $398.69M | $316.49M | $402.57M | $436.47M | $500.15M | $207.25M | — |
| Total Liabilities | $52.51M | $116.97M | $149.46M | $186.99M | $155.41M | $168.65M | — |
| Shareholders' Equity | $346.18M | $199.52M | $253.11M | $249.48M | $344.75M | $38.60M | $7.91M |
| Cash & Equivalents | $112.28M | $69.53M | $66.39M | $59.97M | $142.75M | $28.38M | — |
| Operating Cash Flow | -$138.89M | -$131.50M | -$117.98M | -$109.08M | -$59.53M | $70.07M | — |
| Capital Expenditures | $1.05M | $754.0K | $1.53M | $7.69M | $1.84M | $1.11M | — |
| Shares Outstanding | 135.94M | 107.73M | 102.20M | 88.18M | 87.60M | 40.37M | — |